Durvalumab regimen improves 3-year survival in advanced biliary tract cancers
The addition of durvalumab to chemotherapy doubled 3-year survival among patients with advanced biliary tract cancers, according to data released by the agentās manufacturer. Durvalumab (Imfinzi, AstraZeneca) is a human monoclonal antibody that binds to PD-L1. The agent is approved in the United States for treatment of locally advanced or metastatic biliary tract cancer. It also is